What's happening
This bill directs a study on the impact of requiring health insurance plans to cover treatment for mitochondrial disease.
Why it matters
Could influence future insurance coverage. The study’s findings could directly impact whether treatments for mitochondrial disease become a standard, required benefit in New York health insurance plans, potentially increasing access for patients with this rare, often debilitating condition.
Examines broad financial impacts. By specifically assessing effects on provider costs, insurance premiums, and state finances, the study aims to give policymakers a comprehensive understanding of both the benefits and potential trade-offs of expanding mandatory coverage.
May affect healthcare costs statewide. Depending on the study’s conclusions, there could be downstream effects on how much all New Yorkers pay for insurance, as new coverage mandates can sometimes increase premiums or shift costs across the system.
Brings attention to rare diseases. The bill elevates the profile of mitochondrial disease, possibly driving increased awareness, advocacy, and future policy consideration for individuals with rare or under-recognized health conditions.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Headline styles
Study Insurance for Mito Disease
Plain English, a few words. Used as the page title.
Sponsors
Assembly Member · Assembly District 108
2 Co-sponsors
History
- Referred to health
- Referred to health
Full text
1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
2850
2017-2018 Regular Sessions
IN ASSEMBLY
January 23, 2017
Introduced by M. of A. McDONALD -- read once and referred to the Committee on Health
AN ACT to amend the insurance law, in relation to directing the New York state health care quality and cost containment commission to study and report upon the impact of requiring that certain health insurance plans provide coverage for treatment of mitochondrial disease
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Section 213 of the insurance law is amended by adding a new subsection (e) to read as follows:
(e) The commission shall cause a study to be performed on the impact of requiring certain health insurance plans to provide coverage for treatment of mitochondrial disease. Such study shall include an assessment of the impact of such a requirement on costs to providers, the cost of insurance premiums, and the fiscal impact to the state. The commission shall submit a report of the findings, conclusions and recommendation of such study, on or before November thirtieth, two thousand eighteen, to the governor, the temporary president of the senate, the speaker of the assembly, the chairs of the senate and assembly insurance committees, and the chairs of the senate and assembly health committees.
§ 2. This act shall take effect immediately.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD00580-01-7
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.